|
|
|
|
 |
 |
GlaxoSmithKline Press Releases |
 |
|
|
|
|
25th November, 2003
GlaxoSmithKline reinforces its committment to the Orange Card
GlaxoSmithKline reinforces its committment to the Orange Card
Philadelphia, Pa, November, 25, 2003 - Following passage of legislation to establish a Medicare prescription drug benefit, GlaxoSmithKline (GSK) today reinforced its commitment to supporting the company's Orange Card drug savings program ...
|
24th November, 2003
US Court of Appeals rules in Augmentin patent case
US Court of Appeals rules in Augmentin patent case
London, November 24, 2003 - GlaxoSmithKline (GSK) today announced that the US Court of Appeals for the Federal Circuit in Washington, DC has ruled in favour of Geneva Pharmaceuticals, Teva Pharmaceuticals and Ranbaxy, and upheld lower court rulings that invalidated GSK's US patents for its antibiotic Augmentin ...
|
21st November, 2003
Rapid uptake of Levitra ® (vardenafil HCl) seen among US men with erectile dysfunction
Rapid uptake of Levitra® (vardenafil HCl) seen among US men with erectile dysfunction
West Haven, Conn, and Philadelphia, Pa, November, 21, 2003 - Levitra® (vardenafil HCl) (pronounced luh-VEE-tra) is rapidly capturing a growing percentage of new prescriptions in the oral erectile dysfunction (ED) treatment market, according to data from Verispan Source Prescription Audit (SPA) [formerly called Scott Levin] ...
|
18th November, 2003
GlaxoSmithKline receives US approval of Advair Diskus ® 250/50 for the treatment of COPD associated with chronic bronchitis
GlaxoSmithKline receives US approval of Advair Diskus® 250/50 for the treatment of COPD associated with chronic bronchitis
London, November 18, 2003 - GlaxoSmithKline announced today that Advair Diskus 250/50 (fluticasone propionate 250 mcg and salmeterol inhalation powder 50 mcg) has been approved by the US Food and Drug Administration for use in COPD patients with chronic bronchitis ...
|
17th November, 2003
GlaxoSmithKline stands firm against illegal pharmaceuticals trade
GlaxoSmithKline stands firm against illegal pharmaceuticals trade
Philadelphia, November 17, 2003 GlaxoSmithKine (GSK) today asked a Minnesota state court judge to prevent the Minnesota Attorney General from using the power of his office to pursue an investigation into activity that is lawful and encouraged by the FDA ...
|
17th November, 2003
GlaxoSmithKline gives largest amount of any FTSE 100 company in Guardian Giving List 2003
GlaxoSmithKline gives largest amount of any FTSE 100 company in Guardian Giving List 2003
London, November 17, 2003GlaxoSmithKline (GSK) has, for the second consecutive year, been recorded as giving the largest amount to global good causes of any FTSE 100 company, according to the Guardian's Giving List published today ...
|
13th November, 2003
Multilaw award presented to GlaxoSmithKline
Multilaw award presented to GlaxoSmithKline
Philadelphia, November 13, 2003 -- Multilaw, an
international network of independent law firms, presented its 2003 Multilaw
Award to GlaxoSmithKline (GSK) for the company's Global Community Partnerships
programs ...
|
6th November, 2003
GlaxoSmithKline to extend new R&D model with seventh Centre of Excellence for Drug Discovery
GlaxoSmithKline to extend new R&D model with seventh Centre of Excellence for Drug Discovery
London and Philadelphia, November 6, 2003 -- GlaxoSmithKline (GSK) announces that it will create a seventh Centre of Excellence for Drug Discovery (CEDD), extending the company's new model for pharmaceutical research and development ...
|
28th October, 2003
New study shows continuous use of GlaxoSmithKline's Epivir-HBV significantly delayed liver complications due to chronic hepatitis B
New study shows continuous use of GlaxoSmithKline's Epivir-HBV significantly delayed liver complications due to chronic hepatitis B
Boston, MA, October 28, 2003 - GlaxoSmithKline today announced the results of a new study that showed long-term treatment with Epivir-HBV (lamivudine) delayed clinical progression in chronic hepatitis B patients with advanced fibrosis or cirrhosis by significantly reducing the rate of liver complications including the development of liver cancer ...
|
27th October, 2003
GlaxoSmithKline receives FDA approvable letter for Ariflo (cilomilast) tablets 15 mg
GlaxoSmithKline receives FDA approvable letter for Ariflo (cilomilast) tablets 15 mg
Research Triangle Park, NC, October 27, 2003 - GlaxoSmithKline announced today that it has received an approvable letter from the U.S ...
|
|
|
|
« Previous 10 Next 10 » |
|
|
|
|
